Royal Bank Of Canada Humanigen, Inc Transaction History

Royal Bank Of Canada

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$0.13 - $0.2 $528 - $813	4,065 Added 59.13%	10,940 $1,000
Q1 2023 May 15, 2023	SELL	$0.12 - $0.23 $0 - $0	-4 Reduced 0.06%	6,875 $0
Q4 2022 Feb 14, 2023	SELL	$0.09 - $0.2 $86 - $192	-961 Reduced 12.26%	6,879 $0
Q3 2022 Nov 14, 2022	BUY	$0.15 - $3.02 $144 - $2,914	965 Added 14.04%	7,840 $1,000
Q2 2022 Aug 15, 2022	SELL	$1.76 - $3.33 $5,274 - $9,980	-2,997 Reduced 30.36%	6,875 $12,000
Q1 2022 May 16, 2022	SELL	$1.81 - $3.97 $13,026 - $28,572	-7,197 Reduced 42.16%	9,872 $30,000
Q4 2021 Feb 14, 2022	BUY	$3.66 - $8.22 $23,387 - $52,525	6,390 Added 59.84%	17,069 $62,000
Q3 2021 Nov 15, 2021	BUY	$5.93 - $17.83 $4,322 - $12,998	729 Added 7.33%	10,679 $64,000
Q2 2021 Aug 16, 2021	BUY	$13.54 - $22.74 $134,723 - $226,262	9,950 New	9,950 $172,000

558K

Ticker HGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,661,000
Description
Humanigen, Inc., a clinical-stage biopharmaceutical company, focuses on preventing and treating an immune hyper-response called ?cytokine storm'. Lenzilumab is an antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF). The company is developing lenzilumab as a treatment for cytokine storm associated with...

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

Stay updated on Royal Bank Of Canada with notifications on news.